(Q42677554)

4 November 2017

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype (English)

1 reference

4 November 2017

1 reference

Hai-Ling Qiao

1

1 reference

4 November 2017

Yu-Rong Hu

2

1 reference

4 November 2017

Xin Tian

3

1 reference

4 November 2017

Lin-Jing Jia

4

1 reference

4 November 2017

Na Gao

5

1 reference

4 November 2017

Li-Rong Zhang

6

1 reference

4 November 2017

Yu-Zhong Guo

7

1 reference

4 November 2017

10 January 2006

1 reference

European Journal of Clinical Pharmacology

4 November 2017

1 reference

4 November 2017

62

1 reference

4 November 2017

107-112

1 reference

4 November 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-005-0063-1

4 November 2017

0 references

cites work

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-005-0063-1

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-005-0063-1

A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences

21 January 2018

1 reference

12 December 2020

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

1 reference

12 December 2020

Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism

1 reference

12 December 2020

A comparison of five maintenance therapies for reflux esophagitis

1 reference

12 December 2020

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype

1 reference

12 December 2020

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori

1 reference

12 December 2020

Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole

1 reference

12 December 2020

Oxidative metabolism of lansoprazole by human liver cytochromes P450.

1 reference

12 December 2020

Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations

1 reference

12 December 2020

Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety

1 reference

12 December 2020

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

1 reference

12 December 2020

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects

1 reference

12 December 2020

Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans

1 reference

12 December 2020

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

12 December 2020

Improved high performance liquid chromatographic analysis of omeprazole in human plasma

1 reference

12 December 2020

Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes

1 reference

12 December 2020

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status

1 reference

12 December 2020

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

1 reference

12 December 2020

Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.

1 reference

12 December 2020

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects

1 reference

12 December 2020

Individual and ethnic differences in CYP2C19 activity in Chinese populations.

1 reference

12 December 2020

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

12 December 2020

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

1 reference

12 December 2020

Moving towards individualized medicine with pharmacogenomics

1 reference

12 December 2020

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

1 reference

12 December 2020

Pharmacogenomics of proton pump inhibitors

1 reference

12 December 2020

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography

1 reference

12 December 2020

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

1 reference

12 December 2020

Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

Strategies for medical management of reflux disease

1 reference

12 December 2020

10.1007/S00228-005-0063-1

Identifiers

DOI

1 reference

4 November 2017

1 reference